Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment

European Journal of Internal Medicine

Volumn 30, Issue , 2016, Pages 1-6

  Granata, Antonio ^a   Clementi, Anna ^a,b   Virzì, Grazia Maria ^b,c   Brocca, Alessandra ^b,c,d   De Cal, Massimo ^b,c   Scarfia, Viviana Rosalia ^a   Zanoli, Luca ^e   Ronco, Claudio ^b,c   Corrao, Salvatore ^f,g   Malatino, Lorenzo ^e  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b International Renal Research Institute Vicenza   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f National Relevance Hospital Trust Civico e Benfratelli G di Cristina M Ascoli   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; Cardiorenal syndrome type 4; Cardiovascular risk; Chronic kidney disease; Hypertension; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM SALT; CINACALCET; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM CARBONATE; SEVELAMER;

ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BONE MINERAL; CARBAMOYLATION; CARDIOMYOPATHY; CARDIORENAL SYNDROME; CARDIORENAL SYNDROME TYPE 4; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPERTENSION; META ANALYSIS (TOPIC); OXIDATION; PROTEIN CARBONYLATION; PROTEIN GLYCOSYLATION; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK MANAGEMENT; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); CARDIO-RENAL SYNDROME; COMPLICATION; DISEASE COURSE; HEMODIALYSIS; HYPERTROPHY, LEFT VENTRICULAR; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ATHEROSCLEROSIS; CARDIO-RENAL SYNDROME; DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84959531795     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2016.02.019     Document Type: Review

References (80)

1. C. Ronco, P.A. McCullough, S.D. Anker, I. Anand, N. Aspromonte, S.M. Bagshaw, and et al. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI) Contrib Nephrol 165 2010 54 67
2. C. Ronco, M. Haapio, A.A. House, N. Anavekar, and R. Bellomo Cardiorenal syndrome J Am Coll Cardiol 52 19 2008 1527 1539
3. G.M. Virzi, V. Corradi, A. Panagiotou, F. Gastaldon, D.N. Cruz, M. de Cal, and et al. ADPKD: prototype of cardiorenal syndrome type 4 Int J Nephrol 2011 2010 490795
4. A.S. Levey, J.A. Beto, B.E. Coronado, G. Eknoyan, R.N. Foley, B.L. Kasiske, and et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 32 5 1998 853 906
5. N.B. Shulman, C.E. Ford, W.D. Hall, M.D. Blaufox, D. Simon, H.G. Langford, and et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group Hypertension 13 5 Suppl. 1989 I80 I93
6. R.K. Wali, and W.L. Henrich Chronic kidney disease: a risk factor for cardiovascular disease Cardiol Clin 23 3 2005 343 362
7. P. Jungers, Z.A. Massy, T. Nguyen Khoa, C. Fumeron, M. Labrunie, B. Lacour, and et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study Nephrol Dial Transplant 12 12 1997 2597 2602
8. G. Remuzzi, A. Schieppati, and P. Ruggenenti Clinical practice. Nephropathy in patients with type 2 diabetes N Engl J Med 346 15 2002 1145 1151
9. C. Ronco, D.N. Cruz, and F. Ronco Cardiorenal syndromes Curr Opin Crit Care 15 5 2009 384 391
10. C. Ronco, A.A. House, and M. Haapio Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus Nat Clin Pract Nephrol 4 6 2008 310 311
11. P. Muntner, J. He, L. Hamm, C. Loria, and P.K. Whelton Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States J Am Soc Nephrol 13 3 2002 745 753
12. C. Zoccali, F.A. Benedetto, F. Mallamaci, G. Tripepi, I. Fermo, A. Foca, and et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. CREED investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients J Hypertens 18 9 2000 1207 1213
13. K.L. Wang, H.M. Cheng, S.H. Sung, S.Y. Chuang, C.H. Li, H.A. Spurgeon, and et al. Wave reflection and arterial stiffness in the prediction of 15-year all-cause and cardiovascular mortalities: a community-based study Hypertension 55 3 2010 799 805
14. G.F. Mitchell, S.J. Hwang, R.S. Vasan, M.G. Larson, M.J. Pencina, N.M. Hamburg, and et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study Circulation 121 4 2010 505 511
15. J. Blacher, M.E. Safar, A.P. Guerin, B. Pannier, S.J. Marchais, and G.M. London Aortic pulse wave velocity index and mortality in end-stage renal disease Kidney Int 63 5 2003 1852 1860
16. M.C. Wang, W.C. Tsai, J.Y. Chen, and J.J. Huang Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease Am J Kidney Dis 45 3 2005 494 501
17. S. Laurent, J. Cockcroft, L. Van Bortel, P. Boutouyrie, C. Giannattasio, D. Hayoz, and et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur Heart J 27 2006 2588 2605
18. R.C. Shroff, R. McNair, N. Figg, J.N. Skepper, L. Schurgers, A. Gupta, and et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis Circulation 118 17 2008 1748 1757
19. N. Amabile, A.P. Guerin, A. Leroyer, Z. Mallat, C. Nguyen, J. Boddaert, and et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure J Am Soc Nephrol 16 11 2005 3381 3388
20. P.S. Klassen, E.G. Lowrie, D.N. Reddan, E.R. DeLong, J.A. Coladonato, L.A. Szczech, and et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis J Am Med Assoc 287 12 2002 1548 1555
21. D. Russo, S. Corrao, I. Miranda, C. Ruocco, S. Manzi, R. Elefante, and et al. Progression of coronary artery calcification in predialysis patients Am J Nephrol 27 2 2007 152 158
22. D. Russo, S. Corrao, Y. Battaglia, M. Andreucci, A. Caiazza, A. Carlomagno, and et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis Kidney Int 80 1 2011 Jul 112 118
23. P.R. Gajjala, D. Fliser, T. Speer, V. Jankowski, and J. Jankowski Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease Nephrol Dial Transplant 2015
24. P. Muntner, A. Anderson, J. Charleston, Z. Chen, V. Ford, G. Makos, and et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study Am J Kidney Dis 55 3 2010 441 451
25. D. Calabrese Management of cardiovascular disease in chronic kidney disease: implications for managed care Am J Manag Care 17 Suppl. 15 2011 S412 S418
26. G.C. Roy, S.R. Sutradhar, U.K. Barua, N.C. Datta, C.R. Debnath, M.M. Hoque, and et al. Cardiovascular complications of chronic renal failure - an updated review Mymensingh Med J 21 3 2012 573 579
27. M. Yang, C.H. Fox, J. Vassalotti, and M. Choi Complications of progression of CKD Adv Chronic Kidney Dis 18 6 2011 400 405
28. F. Zannad, M. Kessler, P. Lehert, J.P. Grunfeld, C. Thuilliez, A. Leizorovicz, and et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies Kidney Int 70 7 2006 1318 1324
29. P.H. Pun, R.W. Lehrich, S.R. Smith, and J.P. Middleton Predictors of survival after cardiac arrest in outpatient hemodialysis clinics Clin J Am Soc Nephrol 2 3 2007 491 500
30. M. Chonchol, M. Benderly, and U. Goldbourt Beta-blockers for coronary heart disease in chronic kidney disease Nephrol Dial Transplant 23 7 2008 2274 2279
31. G. Cice, L. Ferrara, A. D'Andrea, S. D'Isa, A. Di Benedetto, A. Cittadini, and et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial J Am Coll Cardiol 41 9 2003 1438 1444
32. K.C. Abbott, F.C. Trespalacios, L.Y. Agodoa, A.J. Taylor, and G.L. Bakris Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality Arch Intern Med 164 22 2004 2465 2471
33. P. Pateinakis, and A. Papagianni Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management Int J Nephrol 2011 2011 938651
34. C.A. Herzog, J.M. Mangrum, and R. Passman Sudden cardiac death and dialysis patients Semin Dial 21 4 2008 300 307
35. J.P. Middleton, and P.H. Pun Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy Kidney Int 77 9 2010 753 755
36. C. Zoccali, F.A. Benedetto, F. Mallamaci, G. Tripepi, G. Giacone, A. Cataliotti, and et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis J Am Soc Nephrol 12 12 2001 2768 2774
37. G. Tripepi, F. Mattace-Raso, E. Sijbrands, J. Witteman, F. Rapisarda, L. Malatino, and et al. Aging and left ventricular mass and function in people with end-stage renal disease J Am Geriatr Soc 59 9 2011 1636 1641
38. F. Locatelli, R.L. Pisoni, C. Combe, J. Bommer, V.E. Andreucci, L. Piera, and et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrol Dial Transplant 19 1 2004 121 132
39. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. de Zeeuw, K.U. Eckardt, and et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032
40. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, D.M. Okamoto, and et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 9 1998 584 590
41. T.B. Drueke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Macdougall, D. Tsakiris, and et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 20 2006 2071 2084
42. A.K. Singh, L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, M. Wolfson, and et al. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 20 2006 2085 2098
43. S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, M. Tonelli, A.X. Garg, and et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease Ann Intern Med 153 1 2010 23 33
44. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 130
45. R. Thomas, A. Kanso, and J.R. Sedor Chronic kidney disease and its complications Prim Care 35 2 2008 329 344 [vii]
46. H. Kramer, R. Toto, R. Peshock, R. Cooper, and R. Victor Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study J Am Soc Nephrol 16 2 2005 507 513
47. S.D. Navaneethan, S.C. Palmer, M. Vecchio, J.C. Craig, G.J. Elder, and G.F. Strippoli Phosphate binders for preventing and treating bone disease in chronic kidney disease patients Cochrane Database Syst Rev 2 2011 CD006023
48. W.N. Suki, R. Zabaneh, J.L. Cangiano, J. Reed, D. Fischer, L. Garrett, and et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients Kidney Int 72 9 2007 1130 1137
49. S.K. Ganesh, A.G. Stack, N.W. Levin, T. Hulbert-Shearon, and F.K. Port Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 10 2001 2131 2138
50. R. Garside, M. Pitt, R. Anderson, S. Mealing, C. Roome, A. Snaith, and et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation Health Technol Assess 11 18 2007 1 167 [iii, xi-xiii]
51. D.L. Andress Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation Kidney Int 69 1 2006 33 43
52. A. Testa, F. Mallamaci, F.A. Benedetto, A. Pisano, G. Tripepi, L. Malatino, and et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients J Bone Miner Res 25 2 2010 313 319
53. A.J. Brown, and E. Slatopolsky Vitamin D analogs: therapeutic applications and mechanisms for selectivity Mol Aspects Med 29 6 2008 433 452
54. M. Freundlich, Y. Quiroz, Z. Zhang, Y. Zhang, Y. Bravo, J.R. Weisinger, and et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol Kidney Int 74 11 2008 1394 1402
55. G.H. Lee, D. Benner, D.L. Regidor, and K. Kalantar-Zadeh Impact of kidney bone disease and its management on survival of patients on dialysis J Ren Nutr 17 1 2007 38 44
56. S.D. Navaneethan, S.C. Palmer, M.J. Schreiber, and G.F. Strippoli Weighing the evidence for treatment of chronic kidney disease mineral and bone disorder Nephrology (Carlton) 14 4 2009 363 366
57. H. Oda, and W.F. Keane Lipid abnormalities in end stage renal disease Nephrol Dial Transplant 13 Suppl. 1 1998 45 49
58. L. De Nicola, M. Provenzano, P. Chiodini, G. D'Arrigo, G. Tripepi, L. Del Vecchio, and et al. Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: multicenter prospective study in Italy Nutr Metab Cardiovasc Dis 25 8 2015 756 762
59. M. Tonelli, C. Isles, G.C. Curhan, A. Tonkin, M.A. Pfeffer, J. Shepherd, and et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 12 2004 1557 1563
60. C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, G. Ruf, and et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 3 2005 238 248
61. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, and et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 14 2009 1395 1407
62. Sharp Collaborative G Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Am Heart J 160 5 2010 785 794 [e710]
63. C. Zoccali, F.A. Benedetto, F. Mallamaci, G. Tripepi, G. Giacone, A. Cataliotti, and et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients J Am Soc Nephrol 15 4 2004 1029 1037
64. R.K. Patel, S. Oliver, P.B. Mark, J.R. Powell, E.P. McQuarrie, J.P. Traynor, and et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging Clin J Am Soc Nephrol 4 9 2009 1477 1483
65. E. Ok, A.G. Basnakian, E.O. Apostolov, Y.M. Barri, and S.V. Shah Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease Kidney Int 68 1 2005 173 178
66. A. Simm Protein glycation during aging and in cardiovascular disease J Proteomics 92 2013 248 259
67. M. Busch, S. Franke, C. Ruster, and G. Wolf Advanced glycation end-products and the kidney Eur J Clin Invest 40 8 2010 742 755
68. P.A. Grimsrud, H. Xie, T.J. Griffin, and D.A. Bernlohr Oxidative stress and covalent modification of protein with bioactive aldehydes J Biol Chem 283 32 2008 21837 21841
69. Y. Matsuyama, H. Terawaki, T. Terada, and S. Era Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease Clin Exp Nephrol 13 4 2009 308 315
70. L. Selmeci Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? Free Radic Res 45 10 2011 1115 1123
71. B. Descamps-Latscha, V. Witko-Sarsat, T. Nguyen-Khoa, A.T. Nguyen, V. Gausson, N. Mothu, and et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients Am J Kidney Dis 45 1 2005 39 47
72. E.A. Stephen, A. Venkatasubramaniam, T.A. Good, and L.D. Topoleski The effect of oxidation on the mechanical response and microstructure of porcine aortas J Biomed Mater Res A 102 9 2014 3255 3262
73. H.J. Kim, and N.D. Vaziri Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure Am J Physiol Renal Physiol 298 3 2010 F662 F671
74. S.A. Reisman, G.M. Chertow, S. Hebbar, N.D. Vaziri, K.W. Ward, and C.J. Meyer Bardoxolone methyl decreases megalin and activates nrf2 in the kidney J Am Soc Nephrol 23 10 2012 1663 1673
75. M.P. Chin, D. Wrolstad, G.L. Bakris, G.M. Chertow, D. de Zeeuw, A. Goldsberry, and et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl J Card Fail 20 12 2014 953 958
76. S.P. Hsu, C.K. Chiang, S.Y. Yang, and C.T. Chien N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients Nephron Clin Pract 116 3 2010 c207 c216
77. G. Tripepi, F. Mattace-Raso, F. Rapisarda, B. Stancanelli, L. Malatino, J. Witteman, and et al. Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease J Hypertens 28 12 2010 2468 2474
78. C. Zoccali, F. Mallamaci, S. Parlongo, S. Cutrupi, F.A. Benedetto, G. Tripepi, and et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease Circulation 105 11 2002 1354 1359
79. C. Zoccali, F. Mallamaci, F.A. Benedetto, G. Tripepi, S. Parlongo, A. Cataliotti, and et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients J Am Soc Nephrol 12 7 2001 1508 1515
80. C. Zoccali, F. Mallamaci, G. Tripepi, F.A. Benedetto, S. Cutrupi, S. Parlongo, and et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease J Am Soc Nephrol 13 1 2002 134 141